Atoltivimab/maftivimab/odesivimab, sold under the brand name Inmazeb, is a fixed-dose combination of three monoclonal antibodies for the treatment of...
20 KB (1,712 words) - 21:09, 26 January 2024
Benznidazole Nifurtimox Ivermectin Ansuvimab Atoltivimab/maftivimab/odesivimab (atoltivimab + maftivimab + odesivimab) No listings in this section. Acetylsalicylic...
67 KB (4,835 words) - 06:05, 31 October 2024
approved treatment for Ebola as of 2019[update], two treatments (atoltivimab/maftivimab/odesivimab and ansuvimab) are associated with improved outcomes. Supportive...
194 KB (18,637 words) - 01:02, 5 October 2024
2020. Saxena D, Kaul G, Dasgupta A, Chopra S (August 2021). "Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus"...
5 KB (167 words) - 18:08, 24 January 2023
Libtayo was approved by the FDA in September 2018. Inmazeb (atoltivimab/maftivimab/odesivimab) is a drug made of three antibodies, developed to treat deadly...
26 KB (2,290 words) - 23:04, 12 September 2024
in nature. As of August 2023[update], treatment known as atoltivimab/maftivimab/odesivimab and experimental ansuvimab were found to be 90% effective...
34 KB (3,526 words) - 23:06, 12 September 2024
Atoltivimab mab human Ebola virus glycoprotein part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus) Atoltivimab...
137 KB (4,083 words) - 21:25, 19 October 2024
Maftivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab...
5 KB (126 words) - 15:08, 6 April 2023
Odesivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab...
4 KB (126 words) - 15:08, 6 April 2023
with atoltivimab/maftivimab/odesivimab and ansuvimab. In October 2020, the US Food and Drug Administration (FDA) approved atoltivimab/maftivimab/odesivimab...
24 KB (2,673 words) - 16:46, 2 November 2024